EUCTR2006-001433-17-DE进行中（未招募）不适用
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximab
Glaxo SmithKline Research and Development Limited0 个研究点目标入组 120 人开始时间: 2006年6月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Patient with follicular lymphoma grade 1 – 2 (defined according to WHO guidelines (World Helath Organization classification of tumours: pathology and genetics of tumours of haematopietic and lymphoid tissues)
- •2) Refractory to rituximab given as monotherapy or in combination with any chemotherapy or to rituximab given as maintenance treatment following R-chemo defined as:
- •a. failure to achieve at least PR to rituximab given as monotherapy or in combination with any chemotherapy; or,
- •b. disease progression while on rituximab (either given as monotherapy or in combination with any chemotherapy or during rituximab maintenance treatment following R-chemo); or,
- •c. disease progression in responders within 6 months of the last dose of rituximab (either given as monotherapy or in combination with any chemotherapy or after rituximab maintenance treatment schedule following R-chemo)
- •Please note that patients should have received at least 4 infusions of rituximab (either given as monotherapy or in combination with any chemotherapy)
- •3) Tumor verified to be CD20+ positive from excisional lymph node biopsy . The excisional lymph node biopsy has to be redone if: no tissue is available for central review or if there is clinical suspicion that the follicular lymphoma has transformed to aggressive lymphoma/higher malignancy grade
- •4) CT scan in screening phase (based on local evaluation) showing: a. 2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or b. 1 clearly demarcated lesion with a largest diameter = 2,0 cm
- •5) ECOG Performance Status of 0, 1, or 2
- •6) Age = 18 years
- •7) Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Previous autologous stem cell transplantation, within 6 months prior to Visit 2
- •2)Previous allogeneic stem cell transplantation
- •3)More than 1 previous radio immunotherapy regimen
- •4)Received radio immunotherapy within 3 months prior to Visit 2
- •5)Received any of the following treatments within 4 weeks prior to Visit 2:
- •Anti-cancer therapy (e.g. alkylating agents, anti-metabolites, purine analogues)
- •Glucocorticoid unless given in doses equivalent to = 10 mg of prednisolone /day
- •6)Received monoclonal antibodies, other than rituximab, within 3 months prior to Visit 2
- •7)Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab
- •8)Clinical suspicion that the follicular lymphoma transformed to aggressive lymphoma (e.g. B-symptoms, fast growing tumor or increasing LDH level) unless a new biopsy, just before study entry, confirms follicular lymphoma
- •9)Known CNS involvement of FL
- •10)Past or current malignancy, except for:
- •Follicular Lymphoma
- •Cervical carcinoma Stage 1B or less
- •Non-invasive basal cell and squamous cell skin carcinoma
- •Malignant melanoma with a complete response of a duration of > 10 years
- •Other cancer diagnoses with a complete response of a duration of > 5 years
- •11)Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
- •12)Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities
- •13)Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
- •14)History of significant cerebrovascular disease
- •15)Known HIV positive
- •16)Positive serology for hepatitis B defined as a positive test for HBsAg and/or a combination of a positive test for anti-HBs and anti-HBc
- •17)Screening laboratory values:
- •platelets < 50 x 10^9/L (unless due to FL involvement of the bone marrow)
- •neutrophils < 1.0 x 10^9/L (unless due to FL involvement of the bone marrow)
- •creatinine > 1.5 times upper normal limit (unless normal creatinine clearance)
- •total bilirubin > 1.5 times upper normal limit (unless due to liver involvement of FL)
- •ALT > 2.5 times upper normal limit (unless due to liver involvement of FL)
- •alkaline phosphatase > 2.5 times upper normal limit (unless due to liver involvement of FL)
- •18)Known hypersensitivity to components of investigational product
- •19)Patients with pleural effusion or ascites of significant degree, defined as:
- •a.Patients with ascites detectable by physical examination, or
- •b.Patients with pleural effusion detectable by physical examination unless due to lymphoma involvement or recent splenectomy
- •20)Life expectancy less than 6 months
- •21)Patients who have received treatment with any non-marketed drug substance or experimental therapy within 4 weeks prior to Visit 2
- •22)Current participation in any other interventional clinical study
- •23)Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
- •24)Breast feeding women or women with a positive pregnancy test at Visit 1
- •25)Women of childbearin
研究者
相似试验
尚未招募
3 期
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapyFolliculair LymphomaLymphnode Cancer10025320NL-OMON29878Genmab9
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabon-Hodgkin Follicular LymphomaClassification code 10003899EUCTR2006-001433-17-DKGenmab A/S162
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabFollicular LimphomaMedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2006-001433-17-ITGLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD161
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabon-Hodgkin Follicular LymphomaMedDRA version: 8.1Level: PTClassification code 10003899Term: B-cell lymphomaEUCTR2006-001433-17-NLGenmab A/S162
进行中（未招募）
不适用
Bioequivalence study with clinical endpoint in the treatment of subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.CTRI/2022/04/042203Amneal EU Limited